IMC-EB10

• Description :

  IMC-EB10 (LY3012218) is an anti-FLT3 monoclonal antibody. IMC-EB10 binds to FLT3 with high affinity (Kd = 158 pM) and blocks the binding of FLT3 ligand to FLT3 (IC50 ≈ 10 nM), thereby inhibiting MAPK, STAT5, and PI3K/Akt signaling in leukemia cells. IMC-EB10 can enhance the anti-leukemic effect of Methotrexate (HY-14519) and inhibit leukemias expressing wild-type or ITD-mutated FLT3 receptors. IMC-EB10 prolongs the survival of acute lymphoblastic leukemia (ALL) cells and primary leukemia samples and reduces engraftment in non-obese diabetic/severe combined immunodeficiency patients. IMC-EB10 is indicated for leukemia research[1][2][3][4].

• Product Name Alternative :

  LY3012218

• UNSPSC :

  12352100

• Target :

  Akt; FLT3; p38 MAPK; PI3K; STAT

• Related Pathways :

  JAK/STAT Signaling; MAPK/ERK Pathway; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• References & Citations :

  [1]Piloto O, et al. IMC-EB10, an anti-FLT3 monoclonal antibody, prolongs survival and reduces nonobese diabetic/severe combined immunodeficient engraftment of some acute lymphoblastic leukemia cell lines and primary leukemic samples. Cancer Res. 2006 May 1;66 (9) :4843-51|[2]Erik Corcoran, et al. Abstract #2923: Preclinical pharmacokinetic and pharmacodynamic evaluation of the anti-FLT3 monoclonal antibody IMC-EB10. Cancer Res 1 May 2009; 69 (9_Supplement) : 2923.|[3]David Surguladze, et al. Synergistic Anti-Leukemic Effect of Combination Therapy with Anti-FLT3 Antibody.IMC-EB10 and Methotrexate, Blood, Volume 112, Issue 11,2008, Page 3964, ISSN 0006-4971, |[4]Li Y, et al. Suppression of leukemia expressing wild-type or ITD-mutant FLT3 receptor by a fully human anti-FLT3 neutralizing antibody. Blood.2004 Aug 15;104 (4) :1137-44.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Inhibitory Antibodies

• Clinical Information :

  No Development Reported

• Isoform :

  STAT5